World's Best Scientists 2026 revealed!
Emmanuel S. Antonarakis

Emmanuel S. Antonarakis

D-Index & Metrics

Medicine

D-Index
87
Citations
37558
World Ranking
13447
National Ranking
6840

Emmanuel S. Antonarakis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Emmanuel S. Antonarakis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,020 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Emmanuel S. Antonarakis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Emmanuel S. Antonarakis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Emmanuel S. Antonarakis is affiliated with the University of Minnesota in the United States and has a significant research presence in medicine, with a focus on oncology and molecular biology. Their work primarily investigates prostate cancer treatment and research, cancer genomics and diagnostics, as well as cancer immunotherapy and biomarkers. Other prominent research areas include radiopharmaceutical chemistry and applications, PARP inhibition in cancer therapy, and cancer metabolism.

Their recent publications include:

  • Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer, 2020, published in JAMA Oncology
  • NCCN Guidelines Insights: Prostate Cancer, Version 1.2021, 2021, published in Journal of the National Comprehensive Cancer Network
  • TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?, 2020, published in Cancer Discovery
  • Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials, 2022, published in Journal of Clinical Oncology
  • CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors, 2020, published in JCO Precision Oncology

Frequent coauthors who have contributed to their work include:

  • Mark C. Markowski
  • Rana R. McKay
  • Samuel R. Denmeade
  • Channing J. Paller
  • Tamara L. Lotan

Their publications are often featured in a variety of clinical and cancer research journals. Frequent publication venues include:

  • Journal of Clinical Oncology (126 papers)
  • The Prostate (17 papers)
  • Annals of Oncology (17 papers)
  • Clinical Cancer Research (13 papers)
  • Cancer Research (13 papers)

In terms of fields of study, their research contributions span:

  • Medicine (707 publications)
  • Biochemistry, Genetics and Molecular Biology (208 publications)

More specific subfields of their work include:

  • Pulmonary and Respiratory Medicine (331 publications)
  • Oncology (175 publications)
  • Cancer Research (111 publications)
  • Radiology, Nuclear Medicine and Imaging (94 publications)
  • Molecular Biology (71 publications)

Main research topics covered in their publications are:

  • Prostate Cancer Treatment and Research (516 publications)
  • Radiopharmaceutical Chemistry and Applications (174 publications)
  • Cancer Immunotherapy and Biomarkers (140 publications)
  • Cancer Genomics and Diagnostics (124 publications)
  • PARP inhibition in cancer therapy (110 publications)
  • Prostate Cancer Diagnosis and Treatment (92 publications)
  • Cancer, Lipids, and Metabolism (68 publications)

Best Publications

  • Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    Chetan Bettegowda;Chetan Bettegowda;Mark Sausen;Rebecca J. Leary;Isaac Kinde

  • AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

    Emmanuel S. Antonarakis;Changxue Lu;Hao Wang;Brandon Luber

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

    James L. Mohler;Emmanuel S. Antonarakis;Andrew J. Armstrong;Anthony V. D'Amico

  • Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial

    Ryan Phillips;William Yue Shi;Matthew Deek;Noura Radwan

  • Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

    Emmanuel S. Antonarakis;Changxue Lu;Brandon Luber;Hao Wang

  • Ruthenium-based chemotherapeutics: are they ready for prime time?

    Emmanuel S. Antonarakis;Ashkan Emadi

  • Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study

    Emmanuel S. Antonarakis;Josep M. Piulats;Marine Gross-Goupil;Jeffrey Goh;Jeffrey Goh

  • Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide

    Emmanuel S. Antonarakis;Changxue Lu;Brandon Luber;Hao Wang

  • Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

    Zsolt Szabo;Esther Mena;Steven P. Rowe;Donika Plyku

  • Prostate cancer, version 1.2021: Featured updates to the nccn guidelines

    Edward Schaeffer;Sandy Srinivas;Emmanuel S. Antonarakis;Andrew J. Armstrong

  • Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

    Philipp Nuhn;Johann S. De Bono;Karim Fizazi;Stephen J. Freedland;Stephen J. Freedland

  • TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?

    Konrad H. Stopsack;Lorelei A. Mucci;Emmanuel S. Antonarakis;Peter S. Nelson

  • Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study

    Andrew J. Armstrong;Susan Halabi;Jun Luo;David M. Nanus

  • The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

    Emmanuel S. Antonarakis;Zhaoyong Feng;Bruce J. Trock;Elizabeth B. Humphreys

  • Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

    Channing J Paller;Emmanuel S Antonarakis

  • Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study

    Michael T. Schweizer;Emmanuel S. Antonarakis;Hao Wang;A. Seun Ajiboye

  • PSMA-Based [ 18 F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer

    Steven P. Rowe;Katarzyna J. Macura;Esther Mena;Amanda L. Blackford

  • Management of Biochemically Recurrent Prostate Cancer After Local Therapy: Evolving Standards of Care and New Directions

    Channing J. Paller;Emmanuel S. Antonarakis

  • Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

    Emmanuel S. Antonarakis;Elisabeth I. Heath;David C. Smith;Dana Rathkopf

Frequent Co-Authors

Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Charles G. Drake
Charles G. Drake Columbia University
Phuoc T. Tran
Phuoc T. Tran Johns Hopkins University School of Medicine
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Andrew J. Armstrong
Andrew J. Armstrong Duke University
Kenneth J. Pienta
Kenneth J. Pienta Johns Hopkins University School of Medicine
Angelo M. De Marzo
Angelo M. De Marzo Johns Hopkins University School of Medicine
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative education pathways can help you accelerate your entry into the healthcare field or advance your existing career. Many students are opting for flexible online degrees to suit their schedules and professional aspirations.

For nurses aiming for the highest clinical qualifications without breaking the bank, there are cheapest online dnp programs. These programs provide advanced practice skills at a lower cost, making leadership and specialized practice roles more accessible.

If you’re looking to start your nursing career quickly, fast track lpn programs offer a streamlined curriculum so you can gain licensure and enter the workforce sooner.

Psychiatry and mental health are growing specialties. Those interested can pursue online msn pmhnp programs to become Psychiatric-Mental Health Nurse Practitioners, providing in-demand care in diverse settings.

Beyond clinical roles, students may consider the online healthcare administration degree for careers in hospital management, healthcare consulting, or policy analysis.

Whichever path you choose, online degree options make it easier to align your education with your career goals in medicine and healthcare.

Best Scientists Citing Emmanuel S. Antonarakis

Trending Scientists

Recently Published Articles